Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis
NCT07213960Phase 3Recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Oct 2029
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pegcetacoplan in focal segmental glomerulosclerosis (FSGS), sponsored by Apellis Pharmaceuticals. Planned start Dec 2026; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07213960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213960.